Drug intelligence / Profile preview

nsaid + triptan

Development stage
Phase 4
Lead developer
Apotex
Modality
Small Molecules
Administration
Oral
01

Overview

A combination of a **nonsteroidal anti-inflammatory drug (NSAID)** and a **triptan** is used mainly for the **acute treatment of migraine**. The most well-studied and widely approved example is the fixed-dose combination of **sumatriptan** (a triptan, serotonin 5-HT₁B/₁D agonist) and **naproxen sodium** (an NSAID that inhibits cyclooxygenase-1 and -2 enzymes, reducing prostaglandin synthesis and inflammation). This combination provides superior efficacy for achieving sustained pain freedom and relief compared to monotherapy with either agent, as each component targets distinct pathophysiological mechanisms in migraine: triptans act on the trigeminovascular system to induce vasoconstriction and block pain signal transmission, while NSAIDs reduce neurogenic inflammation in the trigeminal ganglion and prevent central sensitization. Typical indications are moderate to severe episodic migraine in adults.

Brand names
Treximet
Other names
sumatriptan + naproxentriptan + nsaidsumatriptan-naproxen
02

Targets

HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on nsaid + triptan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nsaid + triptan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call